Anaconda is targeting the large vessel occlusion stroke market, where mechanical thrombectomy is used to remove blood clots from blocked cerebral arteries.
These therapies can require multiple stages, including DNA starting materials, RNA production, targeted delivery technologies, formulation, analytical testing and scalable drug product manufacturing.